Aier Eye Hospital responds to Hong Kong IPO rumors; market value has shrunk by over 70% from its historical peak

Aier Eye Hospital responds to Hong Kong IPO rumors: the company’s market value has shrunk by over 70% from its historical peak. Recently, it acquired land in Changsha and opened new clinics, but negative events involving related parties continue to impact its reputation.

Recent Events

On March 9, 2026, media reports indicated that Aier Eye Hospital was considering an IPO in Hong Kong. The company responded, “Please refer to official announcements,” clearly denying any plans as of 2025. This shift occurs amid a backdrop where the company’s market value has fallen more than 70% from its peak and performance is under pressure, possibly aiming to attract international funding and support globalization strategies. Additionally, on March 11, the company acquired the Phase II Meixi Lake land in Changsha, planning to build a comprehensive eye health industry system. On March 14, the Shanghai Aier Eye Hospital presided over the unveiling of its presbyopia correction MDT clinic, focusing on middle-aged and elderly eye disease treatment needs, reflecting business innovation and layout. On the negative side, ongoing issues such as the related party’s psychiatric hospital insurance fraud scandal and medical disputes continue to affect the company’s reputation.

Recent Stock Performance

As of the close on March 13, Aier Eye Hospital’s stock price was 10.16 yuan, down 1.55% over the past five days, with a trading range of 2.91%. Technical analysis shows the stock is in a consolidation pattern, with the 20-day moving average at 10.46 yuan, Bollinger Band resistance at 10.96 yuan, and support at 9.97 yuan. From March 9 to 13, the total trading volume was 2.467 billion yuan, with a low turnover rate, indicating cautious market sentiment.

Financial Analysis

In the first three quarters of 2025, Aier Eye Hospital reported revenue of 17.484 billion yuan, a year-on-year increase of 7.25%. However, net profit attributable to shareholders was 3.115 billion yuan, down 9.76% year-on-year, marking the first three-quarter profit decline since listing. The main reasons for the profit contraction include an 84.79% year-on-year drop in investment income and increased strategic investments. Gross profit margin decreased to 49.27%. In the third quarter alone, net profit fell by 24.12%, showing a trend of “revenue growth but profit decline.”

Institutional Views

Recent ratings from institutions are neutral, with an average target price of 14.80 yuan, representing a 45.67% upside from the current price. Profit forecasts suggest that net profit growth in 2025 is expected to be 2.50%, with a potential rebound to 12.01% in 2026, mainly driven by new business expansion and internationalization. Currently, institutions conduct frequent research, but the fund holding ratio is only 0.74%, indicating a cautious market sentiment.

The above content is compiled from public information and does not constitute investment advice.